Milestone Pharmaceuticals held an investor call on December 15, 2025, following the FDA approval of CARDAMYST.
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Indication & Usage
CARDAMYST is a calcium channel blocker indicated for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults.
Commercial Plans
The presentation discussed plans for commercializing CARDAMYST, including timing, geographic areas of focus, and sales strategy.
Clinical Perspectives
The call featured insights from Joe Oliveto, President & CEO, and David Bharucha, Chief Medical Officer, providing clinical perspectives on CARDAMYST.
- The FDA approval of CARDAMYST opens up new treatment possibilities for acute PSVT episodes in adults, potentially reducing healthcare costs and empowering patients to manage their symptoms effectively.
- The market acceptance of CARDAMYST and the implementation of Milestone's business model are key factors for the company's future growth and success.
The FDA approval and investor call marked a significant milestone for Milestone Pharmaceuticals, positioning CARDAMYST as a promising solution for PSVT treatment.